3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
41
Non-Muscle Invasive Bladder Neoplasms
25
Colorectal Neoplasms
20
Anus Neoplasms
17
Carcinoma, Transitional Cell
15
Neoplasm Metastasis
12
Carcinoma, Hepatocellular
10
Appendiceal Neoplasms
10
Stomach Neoplasms
9
Peritoneal Neoplasms
9
Pancreatic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasms
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Sarcoma
4
Anal Canal Carcinoma
4
Urologic Neoplasms
3
Urologic Diseases
3
Urinary Bladder Diseases
3
Pseudomyxoma Peritonei
3
Mesothelioma, Malignant
3
Gastrointestinal Neoplasms
3
Carcinoma in Situ
3
Carcinoma
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
Mitomycin
×
Clear all
NCT00454519
2009-02-13
IPHC
Wuhan University
Phase 2
Unknown
60 enrolled